Analytical Data
-
Gene name
gABRa3
- Application
-
Alternative Names
GABA(A) receptor subunit alpha-3
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P34903
-
Expression Region
Gly30~Gly276
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GABRa3, a subunit of the gamma-aminobutyric acid (GABA) receptor, plays a critical role in mediating inhibitory neurotransmission in the central nervous system. The GABA receptors, particularly the GABAA subtype, are pivotal for maintaining the balance between excitation and inhibition in neuronal circuits, influencing various neurological processes including anxiety, sleep, and seizure susceptibility. Research on the recombinant expression of GABRa3 is driven by its potential implications in neuropharmacology and understanding neurological disorders. Alterations in GABRa3 expression or function have been implicated in several conditions, such as epilepsy, anxiety disorders, and schizophrenia. By creating and studying recombinant GABRa3 proteins, researchers aim to elucidate the structural and functional properties of this subunit, facilitating the development of targeted therapeutics that modulate GABAergic signaling. Such studies may also contribute to the identification of novel drug candidates and improve our comprehension of receptor dynamics, ultimately enhancing the treatment options for GABA-related disorders.
